This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Events & Webinars
  • Podcasts
  • Resources
  • Learning Zone
  • Products
  • Service Optimisation & Formularies
  • Risk Minimisation Materials
Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer cross colorful
Bayer for ProfessionalsYour Resource Portal
closesearch
Recent Searches
    You are now leaving BayerPro

    The contents and the policies on the website you are visiting is not controlled by the BayerPRO team.
    Do you wish to continue?

    Prostate Cancer Podcast Series

    Conversations at ESMO 2025
    Considering comorbidities in your mHSPC patients.
    NUBEQA Prescribing Information
    PP-NUB-GB-2752, November 2025
    Conversations at ESMO 2025
    Doublet and triplet therapy in mHSPC – Who is the right patient?
    NUBEQA Prescribing Information
    PP-NUB-GB-2751, November 2025
    ESMO 2025
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2700, October 2025
    ASCO GU 2025
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2229, March 2025